comparemela.com

Latest Breaking News On - Amicus therapeutic - Page 1 : comparemela.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

Ireland
Australia
Canada
Germany
United-states
Spain
Austria
United-kingdom
Switzerland
Japan
Brazil
China

Chiesi survey shows how Fabry drugs are failing patients

Chiesi survey shows how Fabry drugs are failing patients
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Canada
Italy
Italian
Sanofi-fabrazyme
Takeda-replagal
Protalix-biotherapeutics
Amicus-therapeutic
Orphanet-journal

When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable?

Amicus Therapeutics, Inc. ( NASDAQ:FOLD ) is possibly approaching a major achievement in its business, so we would like.

Management-team
Amicus-therapeutics
Amicus-therapeutic
Simply-wall
High-performing-stocks
Biotechnology-company

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript

Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics Full Year 2023 Financial Results Conference Call and Webcast.

United-states
Germany
United-kingdom
San-diego
California
Japan
Austria
Jeff-gatseli
Salveen-richter
Asia-pacific
Simon-harford
Bradley-campbell

Q3 2024 EPS Estimates for Amicus Therapeutics, Inc. Cut by Analyst (NASDAQ:FOLD)

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) – Zacks Research decreased their Q3 2024 earnings estimates for shares of Amicus Therapeutics in a report issued on Thursday, January 18th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their prior estimate of $0.01. […]

China
United-states
America
Ellen-rosenberg
Jeff-castelli
Jpmorgan-chase-co
Zacks-research
Amicus-therapeutics-company-profile
Exchange-traded-concepts
Amicus-therapeutics-inc
Securities-exchange-commission
China-universal-asset-management-co

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.